Introduction: Alcohol use disorder (AUD) is widespread and problematic in the United States, and current pharmacotherapy options have relatively modest effects. Therefore, novel interventions such as ketamine therapy have gained interest as potentially efficacious options, known to generate unique psychotherapeutic experiences. The present secondary analysis examines the acute subjective experiences-both quantitatively and qualitatively-of clinical trial participants with AUD who received intravenous (IV) ketamine therapy in the hospital setting.

Materials And Methods: Among a subset of inpatient clinical trial participants with AUD who received IV ketamine therapy ( = 12), acceptability and tolerability were assessed. Next, a brief directed content analysis was performed, utilizing textual data transcribed immediately after ketamine infusion. Six preselected themes from the literature were chosen to apply to our text.

Results: Among this sample, IV ketamine therapy appeared well tolerated and highly acceptable (mean 9.5 on 0-10 Likert scale). The mean Clinician-Administered Dissociative States Scale (CADSS) score was 21.7 (out of max 92). It seemed to occasion experiences that were largely positive, transporting, visual, and meaningful. The most frequently assigned themes in our data set were "Meaningful, spiritual, and mystical experiences," "Positive affect," and "Inherent contradictions of the acute experience."

Conclusions: Prior themes derived from two theory-generating publications applied widely to our participants' reported experiences. The hospital setting itself did not appear to be a barrier in facilitating these experiences.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658664PMC
http://dx.doi.org/10.1089/psymed.2023.0066DOI Listing

Publication Analysis

Top Keywords

ketamine therapy
20
acute subjective
8
intravenous ketamine
8
alcohol disorder
8
clinical trial
8
trial participants
8
participants aud
8
aud received
8
ketamine
6
experiences
5

Similar Publications

Background: In the postpandemic era, telemedicine continues to enable mental health care access for many people, especially persons living in areas with mental health care provider shortages. However, as lawmakers consider long-term telemedicine policy decisions, some question the safety and appropriateness of prescribing via telemedicine, and whether there should be requirements for in-person evaluation, especially for controlled substances.

Objective: Our objective was to assess US telemental health care provider perceptions of comfort and perceived safety in prescribing medications, including controlled substances, via telemedicine.

View Article and Find Full Text PDF

Assessment of complement cascade components in patients with major depressive disorder.

Brain Behav Immun

March 2025

Pathophysiology of Neuropsychiatric Disorders Program, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Research and Development, Charlie Norwood VA Medical Center, Augusta, GA, USA. Electronic address:

Recent evidence suggests that the rapid-acting antidepressant ketamine has immune regulatory functions. The complement system is an important component of the innate immune response and plays a key role in synaptic plasticity. An increase in complement component 3 (C3) expression was previously found in the prefrontal cortex of individuals with depression.

View Article and Find Full Text PDF

Persistent aura without infarction.

Curr Opin Neurol

March 2025

Mount Sinai School of Medicine, 5 East 98th St, 7th Floor, NY, NY 10029, USA.

Purpose Of Review: The scope of this review is to discuss persistent aura without infarction, a rare, highly disabling, yet apparently benign clinical condition, straddling neurology, neuro-ophthalmology, and psychiatry, whose differential diagnosis is essential for an appropriate therapeutic approach and to avoid clinical complications. Here we attempt to report on the available literature, trying to present a summary, despite the scarcity of available literature.

Recent Findings: Persistent aura without infarction is a diagnostic challenge, likely caused by cortical spreading depression and vasoconstriction, whose clinical features are not always easy to pigeonhole into the available diagnostic criteria.

View Article and Find Full Text PDF

The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.

CNS Neurosci Ther

March 2025

Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou, China.

Aims: Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mechanisms underlying this await comprehensive explication. We used metabolomics to find biomarkers for ketamine efficacy and uncover its mechanisms of action.

Methods: The study included 40 MDD patients treated with ketamine in the discovery cohort and 24 patients in the validation cohort.

View Article and Find Full Text PDF

Ketamine, a rapid-acting antidepressant, has undesirable psychotomimetic effects, including a dissociative effect. There is currently no effective strategy to suppress these side effects while preserving its antidepressant effect. Here, we investigated the effects of a D2/D3 receptor antagonist and partial agonists on the psychotomimetic and antidepressant effects of ketamine in mice and humans.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!